A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

Inclusion Criteria: * Male or female aged 18 years or older * Type 1 or type 2 Diabetes Mellitus * Central-involved DME with central subfield thickness of ≥ 320µm on Spectralis® spectral domain optical coherence tomography (SD-OCT) or ≥ 305µm on non-Spectralis SD-OCT, in the study eye * Best-corrected visual acuity (BCVA) ≤ 62 and ≥ 23 ETDRS letter score in the study eye * Written informed consent obtained from the subject prior to screening procedures Exclusion Criteria: * Macular edema due to causes other than DME * Concurrent disease in the study eye, other than central-involved DME, that could compromise BCVA, require medical or surgical intervention during the study period or could confound interpretation of the results * Any condition that could confound the ability to detect a change in central subfield thickness in the study eye * Previous confounding treatments / procedures, or expected to require confounding treatments / procedures at any time during the study period * Presence of neovascularization at the disc (NVD) in the study eye * Uncontrolled glaucoma in the study eye * Any active ocular / intra-ocular infection or inflammation in either eye * Poorly controlled Diabetes Mellitus * Uncontrolled hypertension